Influenza vaccination rates vary widely in patients with HF
Influenza vaccination rates varied widely, especially by country, among patients with HF with reduced ejection fraction enrolled in the PARADIGM-HF trial. Vaccination in this population was associated with a reduced mortality risk, researchers reported in the Journal of the American College of Cardiology: Heart Failure.
In the PARADIGM-HF trial, researchers compared valsartan/sacubitril (Entresto, Novartis) to the ACE inhibitor enalapril and analyzed the effect on death and HF hospitalization in patients with HF with reduced ejection fraction (HFrEF). According to previously published findings, valsartan/sacubitril was superior to enalapril.
Printed from https://innovationblog.partners.org/influenza-vaccination-rates-vary-widely-in-patients-with-hf · Published 07 Nov 2018
© PARTNERS HEALTHCARE. ALL RIGHTS RESERVED